Abstract:Summary Background Broad-capture proteomic technologies have the potential to improve disease prediction, enabling targeted prevention and management, but studies have so far been limited to very few selected diseases and have not evaluated predictive performance across multiple conditions. We aimed to evaluate the potential of serum proteins to improve risk prediction over and above health-derived information and polygenic risk scores across a diverse set of 24 outcomes. Methods We designed multiple case-cohorts nested in the EPIC-Norfolk prospective study, from participants with available serum samples and genome-wide genotype data, with more than 32 974 person-years of follow-up. Participants were middle-aged individuals (aged 40–79 years at baseline) of European ancestry who were recruited from the general population of Norfolk, England, between March, 1993 and December, 1997. We selected participants who developed one of ten less common diseases within 10 years of follow-up; we also subsampled a randomly drawn control subcohort, which also served to investigate 14 more common outcomes (n>70), including all-cause premature mortality (death before the age of 75 years; case numbers 71–437; controls 608–1556). Individuals were excluded from the current study owing to failed genotyping or proteomic quality control, relatedness, or missing information on age, sex, BMI, or smoking status. We used a machine learning framework to derive sparse predictive protein models for the onset of the the 23 individual diseases and all-cause premature mortality, and to derive a single common sparse multimorbidity signature that was predictive across multiple diseases from 2923 serum proteins. Findings Participants who developed one of ten less common diseases within 10 years of follow-up included 482 women and 507 men, with a mean age at baseline of 64·56 years (8·08). The random subcohort included 990 women and 769 men, with a mean age of 58·79 years (9·31). As few as five proteins alone outperformed polygenic risk scores for 17 of 23 outcomes (median dfference in concordance index [C-index] 0·13 [0·10–0·17]) and improved predictive performance when added over basic patient-derived information models for seven outcomes, achieving a median C-index of 0·82 (IQR 0·77–0·82). This included diseases with poor prognosis such as lung cancer (C-index 0·85 [+/− cross-validation error 0·83–0·87]), for which we identified unreported biomarkers such as C-X-C motif chemokine ligand 17. A sparse multimorbidity signature of ten proteins improved prediction across seven outcomes over patient-derived information models, achieving performances (median C-index 0·81 [IQR 0·80–0·82]) similar to those of disease-specific signatures. Interpretation We show the value of broad-capture proteomic biomarker discovery studies across multiple diseases of diverse causes, pointing to those that might benefit the most from proteomic approaches, and the potential to derive common sparse biomarker panels for prediction of multiple diseases at once. This framework could enable follow-up studies to explore the generalisability of proteomic models and to benchmark these against clinical assays, which are required to understand the translational potential of these findings. Funding Medical Research Council, Health Data Research UK, UK Research and Innovation–National Institute for Health and Care Research, Cancer Research UK, and Wellcome Trust.

Blood protein levels predict leading incident diseases and mortality in UK Biobank

Blood protein assessment of leading incident diseases and mortality in the UK Biobank

Epigenetic scores for the circulating proteome as tools for disease prediction

Large-scale plasma proteomics in the UK Biobank modestly improves prediction of major cardiovascular events in a population without previous cardiovascular disease

Plasma Proteomic Profiles Predict Individual Future Health Risk.

Proteome-wide Assessment of 10,000 Plasma Proteins with Age-Related Diseases and Multi-Morbidity in a Chinese Population

Proteomic signatures improve risk prediction for common and rare diseases

Proteomic Aging Clock Predicts Mortality and Risk of Common Age-Related Diseases in Diverse Populations

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia

Identifying proteomic risk factors for cancer using prospective and exome analyses: 1,463 circulating proteins and risk of 19 cancers in the UK Biobank

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank

Measured and genetically predicted protein levels and cardiovascular diseases in UK Biobank and China Kadoorie Biobank

Association of plasma proteomics with mortality in individuals with and without type 2 diabetes: Results from two population-based KORA cohort studies

A compact protein panel for organ-specific age and chronic disease prediction

Plasma proteomic associations with genetics and health in the UK Biobank

Proteomic prediction of diverse incident diseases: a machine learning-guided biomarker discovery study using data from a prospective cohort study

Proteomic Signature of BMI and Risk of Cardiovascular Disease

Plasma proteomic signatures for type 2 diabetes mellitus and related traits in the UK Biobank cohort

Sex-specific proteomic signatures improve cardiovascular risk prediction for the general population without cardiovascular disease or diabetes

Proteomic Analyses in Diverse Populations Improved Risk Prediction and Identified New Drug Targets for Type 2 Diabetes

A protocol for using human genetic data to identify circulating protein level changes that are the causal consequence of cancer processes.